MONTREAL--(BUSINESS WIRE)--Privately held Caprion Pharmaceuticals Inc. today announced that is has entered into an agreement with Centocor Research and Development, Inc., under which Caprion will provide a number of protein targets for the development of monoclonal antibody and other potential therapeutic products for the treatment of several cancer indications.
